companydata.dkDraupnir Bio ApS: Financial statements 2019
CVR: 38546880
Draupnir Bio ApS (CVR 38546880) has filed annual accounts for 2019. In 2019, the company reported a gross profit of DKK -15,909,546 and a net result of DKK -15,194,060 compared with DKK -2,117,554 the year before. Equity amounted to DKK 51,974,272. The solvency ratio was 97.3%. The company had 2 employees in the financial year.
- Gross Profit
- -15,909,546 kr.
- Profit/Loss
- -15,194,060 kr.
- Equity
- 51,974,272 kr.
- Total Assets
- 53,395,262 kr.
- Employees
- 2
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | - | -15.9 mio. | -15.2 mio. | 52 mio. | 2 |
| 2018 | - | -1.8 mio. | -2.1 mio. | -1.8 mio. | 1 |
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2019
As of October 23, 2019, Simon Glerup Pedersen has joined the board of directors of Draupnir Bio ApS.
As of October 23, 2019, Fiona MacLaughlin has joined the board of directors of Draupnir Bio ApS.
As of October 23, 2019, Stefan Emanuel Luzi has joined the board of directors of Draupnir Bio ApS.
As of October 23, 2019, Peter Hans Andreas Seeberger has left the board of directors of Draupnir Bio ApS.
Draupnir Bio ApS has published its annual report for 2018. Gross profit came to DKK -1,779,479, and the net result was DKK -2,117,554.
About Draupnir Bio ApS
Draupnir Bio ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2017. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Andrew Thomas Hotchkiss. The company's owners include Novo Holdings A/S, Coöperatieve Gilde Healthcare IV U.A. and Danmarks Eksport- og Investeringsfond. Equity amounted to DKK 15,256,000.